Related Experiment Video

Updated: Jan 23, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.2K

PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During

Vanda Téglási1, Orsolya Pipek2, Rita Lózsa3

  • 11st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Clinical Lung Cancer
|June 11, 2019
PubMed
Abstract

Insights

Tumor cell programmed death ligand 1 (PD-L1) expression strongly correlates between primary lung adenocarcinoma and brain metastases. This correlation is unaffected by chemotherapy or steroid therapy, guiding treatment strategies for non-small-cell lung cancer brain metastases.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Non-small-cell lung cancer frequently metastasizes to the brain, with poor prognosis.
  • Immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) axis show promise but rely on PD-L1 expression.
  • Understanding PD-L1 expression in brain metastases is crucial for effective immunotherapy selection.

Purpose of the Study:

  • To compare programmed death ligand 1 (PD-L1) expression in paired primary lung adenocarcinoma and brain metastasis samples.
  • To investigate the influence of systemic therapies on PD-L1 expression in brain metastases.
  • To analyze the immune microenvironment of brain metastases.

Main Methods:

  • Analysis of paired primary lung adenocarcinoma and brain metastasis samples from 61 patients.
  • Assessment of PD-L1 expression on tumor and immune cells, and PD-1 expression on immune cells.
  • Evaluation of the impact of radiotherapy, chemotherapy, and steroid therapy on PD-L1 expression.

Main Results:

  • A significant positive correlation was observed in PD-L1 expression of tumor cells between primary lung adenocarcinoma and brain metastases.
  • Chemotherapy and steroid therapy did not impact the changes in tumor cell PD-L1 expression between primary and metastatic sites.
  • Limited concordance in PD-1/PD-L1 positive immune cells suggests distinct immune microenvironments in brain metastases.

Conclusions:

  • PD-L1 expression on tumor cells is highly correlated between primary lung adenocarcinoma and its brain metastases.
  • This correlation is not significantly altered by chemotherapy or steroid therapy.
  • Brain metastases may develop unique immune microenvironments independent of the primary tumor's immune infiltrate.
Keywords:
Immune checkpointImmune environmentLung adenocarcinomaProgrammed death ligand 1

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.3K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

5.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
83.6K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.5K